ALLERGAN HYPOTENSIVE LIPID PHASE III TRIALS FOR GLAUCOMA SET FOR EARLY 1998; BOTOX 1996 SALES UP 37% TO $67.2 MIL., WHILE DOMESTIC EYE CARE Rx SALES DROP
Executive Summary
Allergan hopes to move one of its hypotensive lipid compounds into Phase III trials for treatment of intraocular pressure associated with glaucoma in early 1998, the company announced April 8.